Trials / Completed
CompletedNCT00847483
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
A Comparison of Latanoprost (Xalatan) With Travoprost (Travatan) and Bimatoprost (Lumigan) in Patients With Elevated Intraocular Pressure. A Twelve-week, Masked Evaluator, Phase IV, Multicenter Study in the United States. (Xalatan vs Travatan vs Lumigan).
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 375 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | latanoprost 0.005% ophthalmic solution | One drop in the evening in the affected eye(s) at 8:00pm |
| DRUG | Travoprost 004% sterile ophthalmic solution | One drop in the evening in the affected eye(s) at 8:00pm |
| DRUG | Bimatoprost .03% sterile ophthalmic solution | One drop in the evening in the affected eye(s) at 8:00pm |
Timeline
- Start date
- 2002-01-01
- Primary completion
- 2002-08-01
- Completion
- 2002-08-01
- First posted
- 2009-02-19
- Last updated
- 2021-02-02
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00847483. Inclusion in this directory is not an endorsement.